INTERNATIONAL PATENT: FUTUREGEN BIOPHARMACEUTICAL (BEIJING) CO., LTD., LI, YUN FILES APPLICATION FOR "ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TL1A AND USE THEREOF"

GENEVA, Aug. 6 -- FUTUREGEN BIOPHARMACEUTICAL (BEIJING) CO., LTD. (2-201, Building 1, #16 Baoshennanjie,Daxing Shengwuyiyao ChanyejidiZhongguancun Science Park, Daxing DistrictBeijing, 102629), LI, Yun (C/o Futuregen Biopharmaceutical (beijing) Co., Ltd2-201, Building 1, #16 Baoshennanjie, Daxing Shengwuyiyao ChanyejidiZhongguancun Science Park, Daxing DistrictBeijing, 102629) filed a patent application (PCT/US2025/012854) for "ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TL1A AND USE THEREOF" on Jan 24, 2025. With publication no. WO/2025/160331, the details related to the patent application was published on Jul 31, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is manage...